Q2 2015 13F Holders as of 30 Jun 2015
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
1,794,505
-
Share change
-
-613,891
-
Total reported value
-
$6,481,000
-
Price per share
-
$3.62
-
Number of holders
-
19
-
Value change
-
-$2,294,804
-
Number of buys
-
6
-
Number of sells
-
11
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q2 2015
As of 30 Jun 2015,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,794,505 shares.
The largest 10 holders included
SABBY MANAGEMENT, LLC, VANGUARD GROUP INC, PERCEPTIVE ADVISORS LLC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Fund Advisors, TFS CAPITAL LLC, BlackRock Institutional Trust Company, N.A., Bank of New York Mellon Corp, NORTHERN TRUST CORP, and M&T BANK CORP.
This page lists
19
institutional shareholders reporting positions in this security
for the Q2 2015 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.